세계의 뼈암 치료제 시장 : 약제 유형별, 적응증별, 유통채널별, 지역별

Global bone cancer drugs market is estimated to be valued at US$ 1,286.4 Mn in 2023, and is expected to exhibit a CAGR of 5.2% during the forecast period (2023-2030).

Global Bone Cancer Drugs Market Share (%), By Drug Type, 2023

The term "bone cancer" refers to a variety of malignancies that in the bones. Normal bone tissues may suffer damage, if the cancer cells spread into a bone. The type of bone cancer depends on the cell and tissue types where the disease first manifests itself. Primary bone malignancies are tumors that originate inside the bone itself. Many cancers that start in the body organs or other tissues can spread to the bones in addition to other body parts. These growths are referred to as metastatic or secondary bone malignancies. Most tumors that metastasis (spread) to the bones are from the breast, prostate, and lung. In bone cancer, abnormal cells in bone grow out of control and destroys the normal bone tissue. It can start in bone or spread to other parts of body (called metastasis). Bone cancer is rare. Most bone tumors are benign, and thus, these are not cancerous and will not spread to other areas of your body. However, these can weaken bones and lead to fractures or other problems. There are a few common types of benign bone tumors: Osteochondroma is the most common. It is common in people under the age of 20. A giant cell tumor is present in leg. In rare cases, these can also be cancerous. Osteoid osteomas often occur in long bones, usually in the early 20s. Osteoblastoma is a rare tumor that grows in the spine and long bones, and occurs primarily in young adults. Enchondromas usually appear in the bones of hands and feet. Often there are no symptoms. It is the most common type of hand tumor. Thus, increasing prevalence of bone cancer is expected to drive growth of the global bone cancer drugs market over the forecast period.

Market Dynamics

Increasing products and approvals by government regulatory bodies is expected to drive growth of the global bone cancer drugs market over the forecast period. For instance, in February 2021, the U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to the bone-targeting radiopharmaceutical samarium-153-DOTMP (CycloSam) for use as a potential therapeutic option for patients with osteosarcoma. The nuclear technology uses low specific activity samarium-153 thatreduces europium contamination, and DOTMP, a chelator designed to prevent off-target migration and at target sites with high bone turnover.

Key features of the study:

• This report provides an in-depth analysis of the global bone cancer drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bone cancer drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co., Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd and Teva Pharmaceutical
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global bone cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drugs market

Detailed Segmentation:

• Global Bone Cancer Drugs Market, By Drug Type:
  • Antimetabolites
  • Anthracyclines
  • Antibiotics
  • Others (RANK ligand inhibitors, etc.)
• Global Bone Cancer Drugs Market, By Disease Indication:
  • Multiple Myeloma
  • Osteosarcoma
  • Chondrosarcoma
  • Ewing's Sarcoma
• Global Bone Cancer Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Bone Cancer Drugs Market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Advaxis, Inc.
  • Cellectar Biosciences, Inc.
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Debiopharm Group
  • Merck & Co
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Drivers
• Restraints
• Opportunities
• Market Trends
• Regulatory Scenario
• New Product Launches/Approvals
• Merger, Acquisition and Collaboration Scenario
• PEST Analysis
• PORTER's Analysis

4. Global Bone Cancer Drugs Market - COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Bone Cancer Drugs Market, By Drug Type, 2023- 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2023-2030
  • Segment Trends
• Antimetabolites
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
• Anthracyclines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
• Others (RANK ligand inhibitors, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)

6. Global Bone Cancer Drugs Market, By Disease Indication, 2023 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Multiple Myeloma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)
• Osteosarcoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)
• Chondrosarcoma
  • Introduction
• Ewing's Sarcoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Bone Cancer Drugs Market, By Distribution Channel, 2023 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2023-2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)

8. Global Bone Cancer Drugs Market, By Region, 2023 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Region, 2023-2030
  • Segment Trends
• North America
  • Market Size and Forecast,and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
  • U.S.
  • Canada
• Europe
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2023-2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

• Company Profiles
  • Advaxis, Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Cellectar Biosciences, Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • OPKO Health, Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Pfizer Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Amgen Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Novartis AG
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Eli Lilly and Company
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Debiopharm Group
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Merck & Co
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Bayer AG
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Bristol-Myers Squibb Company
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Takeda Pharmaceutical
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • F. Hoffmann-La Roche Ltd.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Teva Pharmaceutical
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Analyst Views

10. Section

• References
• Research Methodology
• About us and Sales Contact